Timothy Nelson Email

CEO . MAP Pharmaceuticals

,

Location

LinkedIn

Current Roles

Employees:
138
Revenue:
$27.7M
About
MAP Pharmaceuticals is dedicated to developing and commercializing new therapies for patients suffering from conditions that are not adequately treated by currently available medicines. The company is developing LEVADEXâ„¢ inhaled therapy for the potential treatment of migraine and has reported positive results from the efficacy portion of the first Phase 3 trial of LEVADEX. In addition, MAP Pharmaceuticals generates new pipeline opportunities by applying its proprietary drug particle and inhalation technologies to enhance the therapeutic benefits of proven drugs, while minimizing risk by capitalizing on their known safety, efficacy and commercialization history.
MAP Pharmaceuticals Address

null, null
MAP Pharmaceuticals Email